Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

University of Pittsburgh

Status and phase: Completed; Phase 4

Conditions: Migraine

Treatments: Drug: eletriptan

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00259649

901423

Details and patient eligibility

About

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Full description

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Enrollment: 71 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 18-45 healthy menstruating female

Exclusion criteria

• cardiac or other conditions precluding use of eletriptan

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)